



# SEMPERIT GROUP FY 2023 INVESTOR PRESENTATION

**Karl Haider, CEO**

**Helmut Sorger, CFO**

19 March 2024



# Agenda

## **Key Highlights & Strategy (p.2)**

**Operational Performance (p.11)**

**Financial Performance (p.16)**

**Outlook (p.27)**

**Appendix (p.33)**





**Leading industrial elastomer specialist with diversified product portfolio**

**Semperit is a global pioneer in the production of high-quality elastomer applications for industrial clients with a 200 years' history.**

**We are constantly expanding our global footprint – with technologically sophisticated innovations that keep the world of our customers running.**



## OUR VISION:

Addressing global challenges through sophisticated elastomer applications

### IMPORTANT MEGATRENDS

Climate change | Demographics | Urbanisation | Mobility | Electrification

#### Leading market position

Among the world's leading industrial players with our elastomer products

Market leading brands, customer-focused approach and a globally diversified sales network

#### Technological edge

Strong track record in synthetic and natural rubber applications complemented by new expansion into liquid silicon rubber

Technological lead based on continuous innovation and customer centricity

#### Resilient business model

Diversified portfolio serving a broad customer base in numerous industries

Streamlined organisation with two separate divisions applying cost leadership with a particular focus on customised technical solutions

#### Strong industrial platform

Powerful set-up based on local knowledge and global powerhouse

Industrial customer solutions and drive for operational excellence at all levels to remain competitive

Lean management

## OUR MISSION:

A global leader with advanced and sustainable elastomer materials and solutions





## Strategic focus: profitable growth, customer intimacy and technology leadership

New **divisional structure** evolves around Semperit's **two main business models** and serves as **ideal platform for focused organic and inorganic growth** – while **reducing complexity** and **enabling to scale up business**



### Semperit Industrial Applications

**Cost leadership to harvest volume business**

- **Cost leadership**
- Process and product **innovation**
- Mostly **standardised high-performance products**
- **Lower complexity** in product portfolio
- **Qualified** sales team & high level of sales **excellence**
- High degree of **unification** of products, processes and equipment across our factories



### Semperit Engineered Applications

**Attractive niche specialisation**

- **Leveraging on know-how and engineered technology**
- Focus on **attractive niche markets**
- Strong **focus on customer**
- High level of **customisation**
- **Standardised** innovation & R&D process, reliable & plannable time to market
- **Qualified** sales team & application engineering
- **Project- & tender business**



# Strategic focus for Semperit Industrial Applications



## HOSES – Cost leadership and enlargement of product range


**DH5 investment:** Capacity expansion in Odry/CZ will strengthen Semperit's position as one of the global market leaders for hydraulic hoses.

**Cost leadership** – set by DH5 as new efficiency benchmark and roll out to other plants

Strengthening and **enlargement of highly competitive product range** (e.g. new soft spiral hose range)

**Organic growth strategy for industrial hoses** focusing on product and market development for selected new applications (e.g. peristaltic pumps, concrete pumps, food etc.)

**Geographic expansion** in **North America**



## PROFILES – Focus on Europe and US

**Strengthening our position** in the European construction and industrial markets

Geographic expansion in **North America**

**Enlarging the customer base** via sales excellence and customer intimacy

Focus on **cost and complexity reduction**

**Recycling:** Development of EPDM profiles with a portion of reclaimed materials





# Strategic focus for Semperit Engineered Applications



## BELTING – Levering on existing capacity

**Surpassing the expected global market growth** by using existing capacity

**Coherent product strategy** – heavy and medium strength steel belts and performance textile belts


- Excellent price / performance ratio
- Benchmark in technical support

Working on strategic partnerships with **international mining groups** and **increasing the market share in mining applications** (excl. lignite)

Concentration on **efficiency** and **capacity utilisation**

### Geographic set-up

- Defend and further expand current growth markets



## FORM – Profitable niches and optimized margins

Strong focus on growth with **new Product-Market-Combinations** (PMC's) which are **highly margin accretive**

**Portfolio streamlining** to boost margins

Extension of end-to-end application know how to grow with **customised product/market strategies**

**Playing the niche** (market wise) supported by **economy of scale** (operations wise) using an increased level of automation and streamlined costs

**Geographic focus** on growth markets in Europe and expansion into Americas and APAC



## RICO – Platform for organic and inorganic growth

**Expansion in Thalheim (Austria)** recently completed (incl. 3 production facilities, high-bay warehouse, handling areas and additional office space on an area of more than 10,000 sqm)


Planning production expansion in **US** and **Switzerland**

**Considering smaller add-on acquisitions to exploit market growth** (market for silicone products in Western Europe and the USA to grow by around 7% p.a. until 2027) and leverage tooling expertise

**Geographic expansion** US and APAC



## 2023: Semperit delivered as promised Setting the stage for a new growth platform





# Liquid Silicone Rubber (LSR) – strengthening of technological leadership and leveraging on substantial market growth

Capacity extension at Rico in Thalheim underpins our technological lead in injection molding tools and automation



- Acquisition of Rico allows **complementary offering with high performance advanced materials** focusing on liquid silicone rubber (LSR)
- **Investment of around EUR 40m** in plant and capacity expansion by 2028
- Smaller add-on acquisitions **to exploit substantial market growth for silicone products** in Western Europe and the USA (expected CAGR of ~7% p.a. until 2027) and leverage tooling expertise





## Hoses – EUR 100m investment in Europe's largest hose production

Growth investment to strengthen our position and competitiveness as one of the top global players for hoses

- **Capacity extension** by 24 million meters p.a. plus 3.6 million meters (relocation) up to 135 million meters p.a. in Odry resp. up to 190 million meters overall hoses production
- **Ramp up** of new production facilities in stages beginning in 2025 – **full capacity in 2030**
- **Total investment** of around **EUR 100m**
- **Benefits** include higher efficiency in supply chains and deliveries, reduced emissions and lower transport costs
- **Focus on** a high degree of **automation and sustainability**







# Agenda

**Key Highlights & Strategy (p.2)**

**Operational Performance (p.11)**

**Financial Performance (p.16)**

**Outlook (p.27)**

**Appendix (p.33)**





# Divisional developments of revenues along two very different success factors

Divisional structure evolves around Semperit's **two main business models**

## Semperit Industrial Applications



## Semperit Engineered Applications



## Surgical Operations






# Semperit Industrial Applications 2023

High cyclicalty of commodity business




## Semperit Industrial Applications



## 2023 vs. 2022

Revenue current period  
Revenue comparable period  
EBITDA current period  
EBITDA comparable period



- Hoses: restrained customer behavior based on low market demand and weakness in short-cycle business
- Profiles: impact from weak construction industry with continuing low but stable level and low backlog
- Annual sales down by 27% and EBITDA by 47% as volumes were down
- End of destocking effects but headwinds of slower economic growth
- Focus on efficient and agile organization, customer intimacy and economies of scale – overhead cost measures effective




# Semperit Engineered Applications 2023

Tailwinds from mining, lower raw materials prices and RICO contribution




## Semperit Engineered Applications



## 2023 vs. 2022

Revenue current period  
Revenue comparable period  
EBITDA current period  
EBITDA comparable period



- Belting: ongoing late-cycle demand in mining with supportive pricing and ongoing solid demand
- Form: sales and profits particularly encouraging in mountain applications, solid after-sales handrail business
- Rico: sales contribution of EUR 37.2m since August 2023 and EBITDA of EUR 7.6m based on strong demand in the areas of health systems, food products and mobility
- Annual sales up by 24% and EBITDA by 36% as prices remained high and portfolio optimization supported margins

<sup>1</sup> EBITDA and EBITDA margin Q3 2023 and Q4 2023 adjusted by EUR 4.1m and EUR 2.3m respectively, for one off effects related to the acquisition of the Rico Group





# ESG achievements 2023

## Key focus points in 2023

- Competitive ESG rating year:

- **EcoVadis Platinum**







- **CDP Climate C, Forest C, Water D** (first time disclosing, rating is private)




- Climate scenario analysis** as an important building block of EU Taxonomy and ESRS

- Amended strategy** with additional **focus on D&I**

## Performance 2023



Actual reduction in % as compared to base year 2019



YoY change of incident rate



**Human Rights**



**D&I**

	2021	2022	2023
0 violations	0	0	0
Sites audited	100%	100%	100%
Employees trained	70%	98%	90%
Female ratio	23%	23%	24%
Disabilities	1%	1%	1%




**Supply Chain**

Share of direct material spend from suppliers certified by EcoVadis



**Business Ethics**



	2021	2022	2023
0 violations	0	0	0
Employees trained	>90%	>80%	100%
Comms measures	16	11	47



# Agenda

**Key Highlights & Strategy (p.2)**

**Operational Performance (p.11)**

**Financial Performance (p.16)**

**Outlook (p.27)**

**Appendix (p.33)**





## Financial highlights 2023

New financial arrangements since Q1'2023 based on strategic priorities of industrial transformation

Financing line extended to **EUR 360m**



Lean management and structural cost savings to support operating leverage  
-Original annual run-rate target of 10m exceeded

**EUR 5.8m** of overhead reduction already achieved



Main focus on free cashflow for growth investments, dividends

**EUR 111.5m** after sale of examination gloves business



Strong balance sheet structure

Financial net debt at **EUR 115.2m** and net debt/EBITDA at **1.6x**



Base dividend at EUR 1.50 per share and additional dividend of EUR 3.00 after sale of Sempermed

**EUR 92.6m** dividends in total paid





## Overview of financial KPIs 2021-2023

	2021	2022	2023	Δ 2022/2023
<b>Revenues</b> , in EUR m	1,182.2	779.8	721.1	↘ -7.5%
<b>EBITDA</b> , in EUR m	361.8	100.5	71.8	↘ -28.5%
<b>EBITDA margin</b> , in %	30.6	12.9	10.0	↘ -2.9PP
<b>EBIT</b> , in EUR m	315.0	62.1	34.6	↘ -44.3%
<b>EBIT margin</b> , in %	26.6	8.0	4.8	↘ -3.2PP
<b>Earnings after tax from continued op.</b> in EUR m	3.6	38.4	24.9	↘ -35.2%
<b>Free Cashflow<sup>1</sup></b> , in EUR m	238.4	-2.8	26.3	↗ n/a
<b>CAPEX<sup>2</sup></b> , in EUR m	47.9	54.5	55.6	↗ 2.0%


<sup>1</sup> Free Cashflow before proceeds from sale of the medical business and strategic growth projects

<sup>2</sup> 2023 CAPEX at EUR 55.6m before M&A: includes EUR 36.2m for maintenance and small projects and EUR 19.4m for strategic Growth projects – Rico acquisition at EUR 164.8m not included



## Detail on Last Twelve Month (LTM) view

### Industrial Sector – development of LTM Revenue (EUR m) and EBITDA margin (%)



- Cyclical downturn since Q1'2023 combined with inventory digestion - destocking effect most notable in 2022-23
- Volumes in decline while prices are stable, margins supported by lower raw materials and energy prices
- Q4'2023 partly impacted by seasonality, planned downtime during the winter period and cost savings
- Further focus on agile and slim organization, cash generation and strong balance sheet


■ LTM Revenue in EUR m    — LTM EBITDA margin in %





# Major drivers of operating performance – main building blocks of EBITDA-bridge

in EUR m




Rico effects shown separately, thus price and volume effects of sales, change in inventories, cost of materials, logistics, personnel expenditures, misc. and cost savings do not include Rico-figures



# Working Capital overview

## Components of Working Capital<sup>1</sup>

in EUR m




● Trade Working Capital in % of LTM revenues;

<sup>1</sup> Since 31 December 2022 without Sempermed (examination operations); as of 30 September 2023 including Rico for two months





## CAPEX development 2021-2023




<sup>1</sup> 2021 and 2022 included each EUR 17mn CAPEX of the discontinued operations for the production line P7+ in Kamunting, Malaysia



# Free cash flow before strategic growth investment

in EUR m

2023








## Financial Net Debt Development 2023

- Improved operating cash flow generation on the back of proactive working capital management
- Proceeds from company disposals are major driving force of higher FCF in 2023
- Higher FCF were used for acquisition of Rico Group, strategic growth investments (DH5, Rico) and dividends






# Robust balance sheet structure and financial profile

## Balance sheet structure

**Balance sheet 31/12/2023: EUR 938m**

Balance sheet 31/12/2022: EUR 843m




## Financial profile as of 31 December 2023

- **Cash and cash equivalents** at EUR 113m
- **New financing of EUR 360m** arranged – EUR 33m already used for Odry DH5 extension and EUR 110m line used for Rico acquisition by end of December
- **Financial liabilities** at EUR 228m, have now increased due to new financing arrangements and RICO integration
- **Net financial debt** at EUR -115m from net cash at YE'22 (EUR 54m)
- **Equity ratio** of 45.3% (YE'22: 61.5%)





# Capital allocation and usage of cash





# Agenda

**Key Highlights & Strategy (p.2)**

**Operational Performance (p.11)**

**Financial Performance (p.16)**

**Outlook (p.27)**

**Appendix (p.33)**



- Current cyclical downturn impacts commodity business (SIA) harder due to weak construction- and yellow goods industries
- Diversified markets with different dynamics for SEA – thus more resilient and stable with focus on technology and industrial solutions (e.g. mountain applications, mobility, healthcare)
- Challenging market conditions with first green shoots expected towards the end of 2024 at earliest





- Focus on industrial strategy with profitable growth, customer intimacy and technological leadership
- Distinctive industrial focus on two competitive business models
- Managing the downturn through share of wallet gains and cost programme
- Simplification, lean management and operational efficiency
- Setting up future growth platform for technical solutions and cost leadership



**2024: EBITDA** expected at  
**~EUR 80m**

**2024: CAPEX** expected at  
**~EUR 70m**

40% growth – 60% maintenance and small growth projects

**Dividend proposal to the AGM**  
**~EUR 0.50 per share**



# Five reasons to invest in Semperit

- ▲ 1 Leading market position in elastomer applications with strong industrial base
- ▲ 2 Relentless focus on innovation and technology
- ▲ 3 Resilient business model driven by operating leverage and cost leadership
- ▲ 4 Strong balance sheet and cash generation capacity
- ▲ 5 Value play with recalibrated platform for future growth





## Contact and financial calendar

### Investor Relations Semperit

**Judit Helenyi**, Director Investor Relations

+43 1 79777 - 310

[www.semperitgroup.com/en/ir](http://www.semperitgroup.com/en/ir)

Am Belvedere 10

1100 Vienna, Austria

### Financial Calendar 2024

**19.03.2024**

**23.04.2024**

**15.05.2024**

**13.08.2024**

**07.11.2024**

Publication of 2023 annual financial statements

Annual General Meeting, Vienna

Report on 1-3 2024

Half-year financial report 2024

Report on 1-9 2024

### DISCLAIMER

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms “Semperit” or “Semperit Group” in this presentation refer to the group; “Semperit AG Holding” or “Semperit Aktiengesellschaft Holding” is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as “expect,” “want,” “believe,” “anticipate,” “includes,” “plan,” “assumes,” “estimate,” “projects,” “intends,” “should,” “will,” “shall,” or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete. Statements referring to people are valid for both men and women.



# Agenda

---

**Key Highlights & Strategy (p.2)**

**Operational Performance (p.11)**

**Financial Performance (p.16)**

**Outlook (p.27)**

**Appendix (p.33)**



# Divisions & Group: 2023 vs 2022

in EUR m

## INDUSTRIAL APPLICATIONS (SIA)

## ENGINEERED APPLICATIONS (SEA)

## SEMPERIT GROUP

	2023	2022 <sup>1</sup>	%	2023 <sup>2</sup>	2022 <sup>1</sup>	%	2023 <sup>2</sup>	2022 <sup>1</sup>	%
<b>Revenue</b>	<b>330.8</b>	450.2	-26.5%	<b>351.0</b>	283.8	23.7%	<b>721.1</b>	779.8	-7.5%
<b>EBITDA</b>	<b>46.9</b>	88.0	-46.8%	<b>50.5</b>	37.2	35.8%	<b>71.8</b>	100.5	-28.5%
EBITDA margin	<b>14.2%</b>	-19.6%	+5.4 PP	<b>14.4%</b>	13.1%	+1.3 PP	<b>10.0%</b>	12.9%	-2.9 PP
EBITDA adjusted	<b>46.9</b>	88.1	-46.8%	<b>56.9</b>	32.5	75.2%	<b>81.7</b>	95.8	-14.7%
EBITDA margin adjusted	<b>14.2%</b>	19.6%	-5.4 PP	<b>16.2%</b>	11.4%	+4.8 PP	<b>11.3%</b>	12.3%	-2.9 PP
<b>EBIT</b>	<b>29.7</b>	67.9	-56.2%	<b>33.2</b>	28.1	18.4%	<b>34.6</b>	62.1	-44.3%
EBIT margin	<b>9.0%</b>	15.1%	-6.1 PP	<b>9.5%</b>	9.9%	-0.4 PP	<b>4.8%</b>	8.0%	-3.2 PP
EBIT adjusted	<b>29.7</b>	70.0	-57.5%	<b>39.6</b>	23.4	69.5%	<b>44.5</b>	65.4	-31.9%
EBIT margin adjusted	<b>9.0%</b>	15.5%	-6.6 PP	<b>11.3%</b>	8.2%	+3.1 PP	<b>6.2%</b>	8.4%	-2.2 PP
Earnings after taxes from continued operations	—	—	—	—	—	—	<b>24.9</b>	38.4	-35.2%
Earnings after taxes from discontinued operations	—	—	—	—	—	—	<b>-41.9</b>	-44.0	-4.6%
<b>Earnings after tax</b>	<b>—</b>	—	—	<b>—</b>	—	—	<b>-17.1</b>	-5.6	n.a.
Earnings after tax adjusted	—	—	—	—	—	—	<b>-8.1</b>	3.8	n.a.
<b>Earnings per share in EUR</b>	<b>—</b>	—	—	<b>—</b>	—	—	<b>-0.82</b>	-0.27	n.a.
<b>Additions in tangible and intangible assets</b>	<b>35.3</b>	23.0	53.3%	<b>240.0</b>	9.2	n.a.	<b>277.0</b>	50.1	n.a.

<sup>1</sup> 2022 adjusted for the one-off effect of the net proceeds from the property sale in France in the Belting division (2022: EBITDA, EBIT: EUR 4.7m; earnings after tax: EUR 4.0m), for the net impairments in the former Sempermed segment and the Profiles division (2022: EBIT: EUR -7.9m; earnings after tax: EUR -12.3m) and for the transaction costs (2022: earnings after tax : EUR -8.2m).

<sup>2</sup> 2023 adjusted for one-off severance payments for changes to the Executive Board and for reductions in headcount (2023: EBITDA, EBIT: EUR -2.2m; earnings after tax: EUR -2.1m), one-off effects from the sale of the medical business (2023: EBITDA, EBIT: EUR -1.3m; earnings after tax: EUR -1.3m), transaction costs for Rico (2023: EBITDA, EBIT: EUR -3.3m, earnings after taxes: EUR -3.2m) and from profits of the Rico Group anticipated in the purchase price allocation (2023: EBITDA, EBIT: EUR -3.0m; earnings after taxes: EUR -2.3m).






# Semperit Group (continued operations)

in EUR m


## SEMPERIT GROUP

	FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	FY 2023
<b>Revenue</b>	<b>601.8</b>	181.5	213.3	198.6	186.4	<b>779.8</b>	185.2	189.0	173.4	173.4	<b>721.1</b>
<b>EBITDA</b>	<b>54.0</b>	20.3	33.7	25.9	20.7	<b>100.5</b>	20.8	22.9	13.1	15.0	<b>71.8</b>
EBITDA margin	<b>9.0%</b>	11.2%	15.8%	13.0%	11.1%	<b>12.9%</b>	11.2%	12.1%	7.5%	8.7%	<b>10.0%</b>
<b>EBIT</b>	<b>25.2</b>	12.7	26.2	9.7	13.7	<b>62.1</b>	13.2	15.2	2.4	3.8	<b>34.6</b>
EBIT margin	<b>4.2%</b>	7.0%	12.3%	4.9%	7.3%	<b>8.0%</b>	7.1%	8.1%	1.4%	2.2%	<b>4.8%</b>

### EBITDA



### EBIT





# Semperit Industrial Applications, Semperit Engineered Applications & Corporate

in EUR m

## SEMPERIT INDUSTRIAL APPLICATIONS (SIA)

	FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	FY 2023
Revenue	341.9	111.1	126.4	111.6	101.1	450.2	99.4	93.0	72.2	66.2	330.8
EBITDA	59.2	21.3	30.2	24.0	12.6	88.0	17.5	17.8	7.4	4.2	46.9
EBITDA margin	17.3%	19.1%	23.9%	21.5%	12.5%	19.6%	17.6%	19.2%	10.2%	6.3%	14.2%
EBIT	42.1	16.6	25.7	17.4	8.1	67.9	12.9	13.5	3.1	0.2	29.7
EBIT margin	12.3%	14.9%	20.4%	15.6%	8.0%	15.1%	13.0%	14.5%	4.3%	0.3%	9.0%

## SEMPERIT ENGINEERED APPLICATIONS (SEA)

	FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	FY 2023
Revenue	214.1	59.8	75.0	74.4	74.6	283.8	77.1	86.3	91.5	96.0	351.0
EBITDA	22.9	5.2	11.3	8.4	12.2	37.2	13.1	15.8	7.5	14.0	50.5
EBITDA margin	10.7%	8.7%	15.1%	11.3%	16.4%	13.1%	17.1%	18.3%	8.2%	14.6%	14.4%
EBIT	14.7	3.0	9.1	6.1	9.8	28.1	10.7	13.2	1.9	7.5	33.2
EBIT margin	6.9%	5.1%	12.2%	8.2%	13.1%	9.9%	13.9%	15.3%	2.0%	7.8%	9.5%


## CORPORATE

	FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	FY 2023
EBITDA	-21.5	-3.2	-5.1	-2.2	-8.8	-19.4	-7.3	-8.6	-1.7	-3.3	-21.0
EBIT	-22.7	-3.5	-5.4	-2.5	-9.2	-20.6	-7.7	-9.0	-2.1	-3.6	-22.4




# Surgical Operations

Weak results driven by low demand and price levels



## 2023 vs. 2022



- Closing Sempermed sale (examination gloves and distribution) on August 31, 2023
- Contract manufacturing for Harps started on September 1, 2023
- Surgical results 1-8 2023 still burdened by fully running the surgical business with low demand, price pressure due to excess capacities and negative scale effects





# Key figures 2012-2023

in EUR m

## KEY PERFORMANCE FIGURES

	2012	2013	2014 <sup>1</sup>	2015 <sup>1</sup>	2016 adj. <sup>2</sup>	2017 adj. <sup>3</sup>	2018 adj. <sup>4</sup>	2019 adj. <sup>5</sup>	2020 adj. <sup>6</sup>	2021 <sup>7</sup>	2022 adj. <sup>7</sup>	2023 adj. <sup>8</sup>
<b>Revenue</b>	828.6	906.3	858.3	914.7	852.4	874.2	875.5	840.6	927.5	601.8	779.8	721.1
<b>EBITDA</b>	108.7	132.5	101.9	96.2	74.7	35.8	50.3	63.8	208.6	54.0	95.8	81.7
<b>EBITDA margin</b>	13.1%	14.6%	11.9%	10.5%	8.8%	4.1%	5.7%	7.6%	22.5%	9.0%	12.3%	11.3%
<b>EBIT</b>	72.5	87.8	63.8	66.7	41.1	-0.8	15.4	28.2	171.4	25.2	65.4	44.5
<b>EBIT margin</b>	8.8%	9.7%	7.4%	7.3%	4.8%	-0.1%	1.7%	3.6%	18.5%	4.2%	8.4%	6.2%
<b>Earnings after tax</b>	46.1	54.9	37.8	46.4	15.2	-473.9	-17.3	-0.2	121.9	3.6	10.9	-8.1
<b>EPS, in EUR</b>	2.25	2.65	1.85	2.26	0.74	-2.08	-1.06	-0.33	5.53	10.8	-0.27	-0.82
<b>Gross cash flow</b>	85.6	116.2	89.9	55.7	48.1	32.2	37.4	46.7	193.7	323.4	30.5	24.4
<b>Return on equity</b>	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%	-4.2%	-16.3%	58.0%	45.7%	-1.1%	-4.0%

## BALANCE SHEET KEY FIGURES

	2012	2013	2014 <sup>2</sup>	2015 <sup>2</sup>	2016	2017	2018	2019	2020	2021 <sup>7</sup>	2022 <sup>7</sup>	2023 <sup>8</sup>
<b>Balance sheet total</b>	824.5	852.1	826.3	937.8	1,034.5	853.2	768.8	701.8	764.4	958.6	842.9	937.9
<b>Equity</b>	406.2	411.5	443.8	363.3	329.3	278.5	329.5	237.4	332.3	540.1	518.2	425.3
<b>Equity ratio</b>	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%	42.9%	39.0%	43.5%	56.3%	61.5%	45.3%
<b>Investments in tangible and intangible assets</b>	41.2	49.7	67.4	71.8	65.1	74.5	80.8	31.9	26.4	34.6	37.6	277.0
<b>Employees, at balance sheet date, FTEs</b>	9,577	10,276	6,888	7,053	6,974	6,838	6,773	6,902	6,943	n.a.	4,269	4,576


<sup>1</sup> 2014 & 2015 restated. <sup>2</sup> 2016 without profit contribution from SSC / Thai glove JV, impairment Sempermed and trade tax / levies in Brazil. <sup>3</sup> 2017 adjusted for positive one-off effects from JV transaction of EUR 85m (EUR 65m for net profit) and negative one-off effects from impairment at Sempermed (EUR 26m adj. EBIT, EAT only), from restructuring expenses in France (EUR 11m), valuation adjustment in IT (EUR 4m EBITDA, EUR 3m EBIT) & expenses resulting from tax audit in Austria (EUR 5m, mainly for refund of energy supply charge). <sup>4</sup> 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (EUR 4m for EBITDA, EUR 8m for EBIT and EAT) and for impairment of Sempermed of EUR 55m (adj. for EBIT and EAT only). <sup>5</sup> FY 2019 adjusted for positive one-off effects of EUR 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of EUR 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT). <sup>6</sup> 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2m EUR; earnings after tax effect: EUR +88.8m) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR -19.8m; earnings after taxes effect: EUR -16.1m) <sup>7</sup> Numbers in 2021 and 2022 refer to new Group-structure, i.e. reflect the sale of Sempermed; 2022 adjusted for the one-off effect of the net proceeds from the property sale in France (2022: EBITDA, EBIT: EUR 4.7m; EAT: EUR 4.0m), for net impairments (2022: EBIT: EUR -7.9m; EAT: EUR -12.3m) and for the transaction costs (2022: EAT: EUR -8.2m). <sup>8</sup> 2023 adjusted for one-off severance payments for changes to the Executive Board and for reductions in headcount (2023: EBITDA, EBIT: EUR -2.2m; EAT: EUR -2.1m), one-off effects from the sale of the medical business (2023: EBITDA, EBIT: EUR -1.3m; EAT: EUR -1.3m), transaction costs for Rico (2023: EBITDA, EBIT: EUR -3.3m, EAT: EUR -3.2m) and from profits of the Rico Group anticipated in the purchase price allocation (2023: EBITDA, EBIT: EUR -3.0m; EAT: EUR -2.3m).



## Overview price indices Butadiene

Price movements for raw materials<sup>1)</sup> became highly unpredictable

Price indices Butadiene as main raw material for synthetic rubber / latex




<sup>1)</sup> Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0




## Overview price indices LFO-F-NWE / wire rod

Significant increase for raw material<sup>1)</sup> used in industrial segments

Price index LFO-F-NWE



Price index wire rod



<sup>1)</sup> Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



## ESG targets adapted to the new Group structure

**ESG Ratings:** EcoVadis platinum award for **second year** in a row

**CDP -Climate Change improved** to C (after C-), first rating for Forest (C)

**Diversity & Inclusion (D&I) as focus point** introduced while also applying new targets

More **ambitious goal** set **for supply chains** to expand positive impact on Semperit's total sustainability footprint

### Energy<sup>1,2</sup>:

**5%** reduction by 2030



### Waste<sup>2</sup>:

**7%** reduction by 2030



### Emissions<sup>2</sup>:

**10%** reduction by 2030



### Incidence rate<sup>1,2</sup>:

**8%** reduction year over year



### D&I Gender:

**0.5%** overall female increase  
**1%** female leadership increase  
**1%** higher senior leadership (annual change in each case)



### Supply chain<sup>1</sup>:

**75%** of total spend to be covered by EcoVadis by 2030



1 Part of the ESG-based financing as of 31.8.2023

2 Baseline 2023, including Rico and Surgical